晚期特发性肺纤维化患者抗纤维化治疗的真实世界多中心队列结局
该研究纳入四个北欧国家IPF注册库的502例患者,比较启动抗纤维化治疗时晚期IPF(FVC<50%和/或DLCO<30%预计值)与轻中度IPF的结局。结果显示晚期IPF患者FVC年变化为+28 ml(95%CI -96, +152),轻中度患者为-125 ml(95%CI -163, -87);晚期IPF与更差的无移植生存(HR 2.39, 95%CI 1.66, 3.43)及无进展无移植生存(HR 1.60, 95%CI 1.15, 2.23)相关。
要点
- 晚期IPF启动抗纤维化治疗后肺功能下降速度未高于轻中度IPF。
- 晚期IPF患者无移植生存及无进展无移植生存显著更差。
- 需前瞻性研究确定抗纤维化治疗对晚期IPF的疗效。
核心结论
- 在广泛代表性的IPF人群中,启动抗纤维化治疗时晚期IPF患者肺功能下降未大于轻中度IPF,但死亡率显著更高。
研究设计与样本
- 研究纳入四个北欧国家IPF注册库的502例患者,其中66例(13%)为晚期IPF。
- 采用线性混合模型评估FVC和DLCO随时间变化,Cox比例风险模型评估无移植生存及无进展无移植生存。
主要发现
- 轻中度IPF患者FVC年变化为-125 ml(95%CI -163, -87),晚期IPF患者为+28 ml(95%CI -96, +152)。
- 治疗启动时晚期IPF与更差的无移植生存相关(HR 2.39, 95%CI 1.66, 3.43)。
- 治疗启动时晚期IPF与更差的无进展无移植生存相关(HR 1.60, 95%CI 1.15, 2.23)。
关键数值与推荐
- 晚期IPF定义为FVC<50%和/或DLCO<30%预计值。
临床怎么用
- 真实世界中晚期IPF患者启动抗纤维化治疗后肺功能下降未加速,但死亡风险仍高,需密切监测。
局限性
- 晚期IPF患者样本量较小(66例),且为注册库观察性研究,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Antifibrotic therapy with nintedanib or pirfenidone slows disease progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF). However, patients with advanced IPF, as defined by forced vital capacity (FVC) < 50% and/or diffusion capacity for carbon monoxide (DLCO) < 30% of predicted, have not been included in randomized trials, and the outcomes of such patients who initiate treatment are not well understood. We determined lung function, disease progression and mortality outcomes following initiation of antifibrotic therapy in patients with advanced IPF at the time of treatment initiation compared to those with mild-moderate IPF. METHODS: We included 502 patients enrolled in IPF registries from four Nordic countries. Linear mixed models were used to assess change in FVC and DLCO over time. Cox proportional hazards models were used to assess transplant-free survival and progression- and transplant-free survival. RESULTS: Of 502 patients, 66 (13%) had advanced IPF. Annual change in FVC was -125 ml (95% CI -163, -87) among patients with mild-moderate IPF, and +28 ml (95% CI -96, +152) among those with advanced IPF. Advanced IPF at treatment initiation was associated with poorer transplant-free survival (hazard ratio [HR] 2.39 [95% CI 1.66, 3.43]) and progression- and transplant-free survival (HR 1.60 [95% CI 1.15, 2.23]). CONCLUSION: In a broadly representative IPF population, patients with advanced IPF at the initiation of antifibrotic therapy did not have greater lung function decline over time compared with those with mild-moderate IPF, but had substantially higher mortality. Prospective studies are needed to determine the effect of antifibrotic therapy in patients with advanced IPF.
引用
- Durheim MT, Bendstrup E, Carlson L, et al. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology. 2021. PMID: 34291523. doi:10.1111/resp.14116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。